GILLIS JONATHAN sold $1.4M of MPLT
GILLIS JONATHAN (CAO and Interim CFO) sold 36,979 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $37.12 ($36.13–$38.17, $1.37M total) across 7 trades over 2026-07-15 to 2026-07-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale amount, share count, trade date range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 designation generally limits interpretive impact.
What to watch
The filing does not disclose reasons for the sale, and it is not accompanied by any new operational, clinical, or financial catalyst.
Background
This is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc., reported by an officer (CAO and interim CFO).
Ticker impact
MapLight Therapeutics CAO and interim CFO Jonathan Gillis sold about 36,979 shares in open-market trades for roughly $1.37M under a 10b5-1 plan.
Likely limited near-term price impact; any reaction would be sentiment-driven rather than fundamental.
The filing provides transaction size, dates, and that it was executed under a pre-arranged 10b5-1 plan, which typically dampens interpretive value.
Market effects
No direct sector read-through; this is a single-company insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the trades were executed under a 10b5-1 plan, the sale may reflect routine liquidity planning rather than a bearish view on the business.
Key entities
- issuerMapLight Therapeutics, Inc.
Subject of the Form 4 insider sale by its CAO and interim CFO.
- insiderGillis Jonathan
Officer (CAO and interim CFO) who sold shares in open-market trades under a 10b5-1 plan.